Disease on EC 3.4.21.109 - matriptase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Acidosis
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Adenocarcinoma
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Adenocarcinoma
Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients.
Adenocarcinoma
Expression and prognostic value of matriptase in ovarian serous adenocarcinoma.
Adenocarcinoma
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Adenocarcinoma
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Adenocarcinoma
Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front.
Adenocarcinoma
Targeted HAI-2 deletion causes excessive proteolysis with prolonged active prostasin and depletion of HAI-1 monomer in intestinal but not epidermal epithelial cells.
Adenocarcinoma
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Adenocarcinoma
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma.
Adenocarcinoma
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Adenocarcinoma, Mucinous
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Adenoma
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
Adenoma
The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals.
Anemia
A critical role for murine transferrin receptor 2 in erythropoiesis during iron restriction.
Anemia
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.
Anemia
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron.
Anemia
A novel homozygous nonsense mutation (p.Y78*) in TMPRSS6 gene causing iron-refractory iron deficiency anemia (IRIDA) in two siblings.
Anemia
A novel mutation Gly603Arg of TMPRSS6 in a Korean female with iron-refractory iron deficiency anemia.
Anemia
A Novel mutation in the CUB sequence of matriptase-2 (Tmprss6) is implicated in iron-resistant iron deficiency anaemia (IRIDA).
Anemia
A novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia - response to Jaspers et al.
Anemia
A novel splice site mutation c.2278 (-1) G>C in the TMPRSS6 gene causes deletion of the substrate binding site of the serine protease resulting in refractory iron deficiency anaemia.
Anemia
A novel splicing mutation of TMPRSS6 in a Chinese child with iron-refractory iron deficiency anaemia.
Anemia
A novel tri-allelic mutation of TMPRSS6 in iron-refractory iron deficiency anaemia with response to glucocorticoid.
Anemia
A strong anti-inflammatory signature revealed by liver transcription profiling of Tmprss6-/- mice.
Anemia
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine ?-thalassemia intermedia.
Anemia
Anaemia, iron deficiency and a common polymorphism of iron-regulation, TMPRSS6 rs855791, in Rwandan children.
Anemia
Associations of Common Variants in HFE and TMPRSS6 Genes with Hepcidin-25 and Iron Status Parameters in Patients with End-Stage Renal Disease.
Anemia
Candidate gene sequencing of SLC11A2 and TMPRSS6 in a family with severe anaemia: common SNPs, rare haplotypes, no causative mutation.
Anemia
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of ?-thalassemia intermedia.
Anemia
Cryptic splice site usage leading to truncated TMPRSS6 is responsible for Iron Refractory Iron Deficiency Anaemia (IRIDA) in an Italian Family.
Anemia
EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency.
Anemia
Evaluation of the level of selected iron-related proteins/receptors in the liver of rats during separate/combined vanadium and magnesium administration.
Anemia
Functional analysis of Matriptase-2 mutations and domains: Insights into the molecular basis of iron refractory iron deficiency anemia.
Anemia
Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.
Anemia
Genetic analysis of TMPRSS6 gene in Saudi female patients with iron deficiency anemia.
Anemia
Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
Anemia
Haematologic data, iron parameters and molecular findings in two new cases of iron-refractory iron deficiency anaemia.
Anemia
Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators: a systematic review with meta-analyses.
Anemia
Iron deficiency anemia due to matriptase-2 inactivation is dependent upon the presence of functional Bmp6.
Anemia
Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.
Anemia
Iron Refractory Iron Deficiency Anemia (IRIDA): A heterogeneous disease that is not always iron refractory.
Anemia
Iron Refractory Iron Deficiency Anemia Due to 374 Base Pairs Deletion in the TMPRSS6 Gene.
Anemia
Iron Refractory Iron Deficiency Anemia in Dizygotic Twins Due to a Novel TMPRSS6 Gene Mutation in Addition to Polymorphisms Associated With High Susceptibility to Develop Ferropenic Anemia.
Anemia
Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy.
Anemia
Iron-refractory iron deficiency anemia (IRIDA) cases with 2 novel TMPRSS6 mutations.
Anemia
Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency?
Anemia
Is the acronym IRIDA acceptable for slow responders to iron in the presence of TMPRSS6 mutations?
Anemia
Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.
Anemia
Liver HFE protein content is posttranscriptionally decreased in iron-deficient mice and rats.
Anemia
Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Humans and Mice.
Anemia
Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis.
Anemia
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
Anemia
Microcytic anaemia with low transferrin saturation, increased serum hepcidin and non-synonymous TMPRSS6 variants: not always iron-refractory iron deficiency anaemia.
Anemia
Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model.
Anemia
Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia.
Anemia
N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding.
Anemia
Novel missense mutation in the TMPRSS6 gene in a Japanese female with iron-refractory iron deficiency anemia.
Anemia
Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA).
Anemia
Rapid, accurate detection of TMPRSS6 gene causative mutations with a high-resolution melting assay.
Anemia
Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signalling & iron homeostasis.
Anemia
RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of ?-thalassemia intermedia.
Anemia
Role of TMPRSS6 rs855791 (T > C) polymorphism in reproductive age women with iron deficiency anemia from Lahore, Pakistan.
Anemia
Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6.
Anemia
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of ?-thalassaemia.
Anemia
Systematic evaluation of paediatric cohort with iron refractory iron deficiency anaemia (IRIDA) phenotype reveals multiple TMPRSS6 gene variations.
Anemia
The role of TMPRSS6 gene variants in iron-related hematological parameters in Turkish patients with iron deficiency anemia.
Anemia
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment.
Anemia
The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin.
Anemia
TMPRSS6 rs855791 polymorphism and susceptibility to iron deficiency anaemia in non-dialysis chronic kidney disease patients in South Africa.
Anemia
TMPRSS6 rs855791 polymorphism influences the susceptibility to iron deficiency anemia in women at reproductive age.
Anemia
TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia.
Anemia
Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency.
Anemia
Two novel mutations in TMPRSS6 associated with iron-refractory iron deficiency anemia in a mother and child.
Anemia
Two Novel TMPRSS6 Variants in a Compound Heterozygous Child With Iron Refractory Iron Deficiency Anemia (IRIDA).
Anemia
Very high frequency of TMPRSS6 gene variations in iron deficiency anaemia of patients with polyendocrine autoimmune syndromes: more than a casual association?
Anemia
[Iron deficiency and overload. Implications in oxidative stress and cardiovascular health]
Anemia, Iron-Deficiency
A child with severe iron-deficiency anemia and a complex TMPRSS6 genotype.
Anemia, Iron-Deficiency
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.
Anemia, Iron-Deficiency
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron.
Anemia, Iron-Deficiency
A novel homozygous nonsense mutation (p.Y78*) in TMPRSS6 gene causing iron-refractory iron deficiency anemia (IRIDA) in two siblings.
Anemia, Iron-Deficiency
A novel mutation Gly603Arg of TMPRSS6 in a Korean female with iron-refractory iron deficiency anemia.
Anemia, Iron-Deficiency
A Novel mutation in the CUB sequence of matriptase-2 (Tmprss6) is implicated in iron-resistant iron deficiency anaemia (IRIDA).
Anemia, Iron-Deficiency
A novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia - response to Jaspers et al.
Anemia, Iron-Deficiency
A novel splice site mutation c.2278 (-1) G>C in the TMPRSS6 gene causes deletion of the substrate binding site of the serine protease resulting in refractory iron deficiency anaemia.
Anemia, Iron-Deficiency
A novel splicing mutation of TMPRSS6 in a Chinese child with iron-refractory iron deficiency anaemia.
Anemia, Iron-Deficiency
A novel tri-allelic mutation of TMPRSS6 in iron-refractory iron deficiency anaemia with response to glucocorticoid.
Anemia, Iron-Deficiency
A strong anti-inflammatory signature revealed by liver transcription profiling of Tmprss6-/- mice.
Anemia, Iron-Deficiency
Candidate gene sequencing of SLC11A2 and TMPRSS6 in a family with severe anaemia: common SNPs, rare haplotypes, no causative mutation.
Anemia, Iron-Deficiency
Cryptic splice site usage leading to truncated TMPRSS6 is responsible for Iron Refractory Iron Deficiency Anaemia (IRIDA) in an Italian Family.
Anemia, Iron-Deficiency
EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency.
Anemia, Iron-Deficiency
Functional analysis of Matriptase-2 mutations and domains: Insights into the molecular basis of iron refractory iron deficiency anemia.
Anemia, Iron-Deficiency
Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies.
Anemia, Iron-Deficiency
Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.
Anemia, Iron-Deficiency
Genetic analysis of TMPRSS6 gene in Saudi female patients with iron deficiency anemia.
Anemia, Iron-Deficiency
Genetic variability of TMPRSS6 and its association with iron deficiency anaemia.
Anemia, Iron-Deficiency
Haematologic data, iron parameters and molecular findings in two new cases of iron-refractory iron deficiency anaemia.
Anemia, Iron-Deficiency
Inactive matriptase-2 mutants found in IRIDA patients still repress hepcidin in a transfection assay despite having lost their serine protease activity.
Anemia, Iron-Deficiency
Into the matrix: regulation of the iron regulatory hormone hepcidin by matriptase-2.
Anemia, Iron-Deficiency
Iron deficiency anemia due to matriptase-2 inactivation is dependent upon the presence of functional Bmp6.
Anemia, Iron-Deficiency
Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.
Anemia, Iron-Deficiency
Iron Refractory Iron Deficiency Anaemia: A Rare Cause of Iron Deficiency Anaemia.
Anemia, Iron-Deficiency
Iron Refractory Iron Deficiency Anemia (IRIDA): A heterogeneous disease that is not always iron refractory.
Anemia, Iron-Deficiency
Iron Refractory Iron Deficiency Anemia Due to 374 Base Pairs Deletion in the TMPRSS6 Gene.
Anemia, Iron-Deficiency
Iron Refractory Iron Deficiency Anemia in Dizygotic Twins Due to a Novel TMPRSS6 Gene Mutation in Addition to Polymorphisms Associated With High Susceptibility to Develop Ferropenic Anemia.
Anemia, Iron-Deficiency
Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy.
Anemia, Iron-Deficiency
Iron-deficiency anemia secondary to mutations in genes controlling hepcidin.
Anemia, Iron-Deficiency
Iron-refractory iron deficiency anemia (IRIDA) cases with 2 novel TMPRSS6 mutations.
Anemia, Iron-Deficiency
Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency?
Anemia, Iron-Deficiency
Is the acronym IRIDA acceptable for slow responders to iron in the presence of TMPRSS6 mutations?
Anemia, Iron-Deficiency
Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.
Anemia, Iron-Deficiency
Liver hemojuvelin protein levels in mice deficient in matriptase-2 (Tmprss6).
Anemia, Iron-Deficiency
Liver HFE protein content is posttranscriptionally decreased in iron-deficient mice and rats.
Anemia, Iron-Deficiency
Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Humans and Mice.
Anemia, Iron-Deficiency
Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis.
Anemia, Iron-Deficiency
Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis.
Anemia, Iron-Deficiency
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
Anemia, Iron-Deficiency
Microcytic anaemia with low transferrin saturation, increased serum hepcidin and non-synonymous TMPRSS6 variants: not always iron-refractory iron deficiency anaemia.
Anemia, Iron-Deficiency
Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia.
Anemia, Iron-Deficiency
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).
Anemia, Iron-Deficiency
N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding.
Anemia, Iron-Deficiency
Novel missense mutation in the TMPRSS6 gene in a Japanese female with iron-refractory iron deficiency anemia.
Anemia, Iron-Deficiency
Novel mutation in the TMPRSS6 gene with iron-refractory iron deficiency anemia.
Anemia, Iron-Deficiency
Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA).
Anemia, Iron-Deficiency
Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia.
Anemia, Iron-Deficiency
Rapid, accurate detection of TMPRSS6 gene causative mutations with a high-resolution melting assay.
Anemia, Iron-Deficiency
Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signalling & iron homeostasis.
Anemia, Iron-Deficiency
Responsiveness to oral iron and ascorbic acid in a patient with IRIDA.
Anemia, Iron-Deficiency
Role of TMPRSS6 rs855791 (T > C) polymorphism in reproductive age women with iron deficiency anemia from Lahore, Pakistan.
Anemia, Iron-Deficiency
Systematic evaluation of paediatric cohort with iron refractory iron deficiency anaemia (IRIDA) phenotype reveals multiple TMPRSS6 gene variations.
Anemia, Iron-Deficiency
The role of TMPRSS6 and HFE variants in iron deficiency anemia in celiac disease.
Anemia, Iron-Deficiency
The role of TMPRSS6 gene variants in iron-related hematological parameters in Turkish patients with iron deficiency anemia.
Anemia, Iron-Deficiency
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment.
Anemia, Iron-Deficiency
Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
Anemia, Iron-Deficiency
TMPRSS6 rs855791 polymorphism and susceptibility to iron deficiency anaemia in non-dialysis chronic kidney disease patients in South Africa.
Anemia, Iron-Deficiency
TMPRSS6 rs855791 polymorphism influences the susceptibility to iron deficiency anemia in women at reproductive age.
Anemia, Iron-Deficiency
TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia.
Anemia, Iron-Deficiency
Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency.
Anemia, Iron-Deficiency
Two novel mutations in the tmprss6 gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form.
Anemia, Iron-Deficiency
Two novel mutations in TMPRSS6 associated with iron-refractory iron deficiency anemia in a mother and child.
Anemia, Iron-Deficiency
Two Novel TMPRSS6 Variants in a Compound Heterozygous Child With Iron Refractory Iron Deficiency Anemia (IRIDA).
Anemia, Iron-Deficiency
Very high frequency of TMPRSS6 gene variations in iron deficiency anaemia of patients with polyendocrine autoimmune syndromes: more than a casual association?
Anemia, Iron-Deficiency
[Iron deficiency and overload. Implications in oxidative stress and cardiovascular health]
beta-Thalassemia
Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
Bile Duct Neoplasms
Overexpression of matriptase in tumor stroma is a poor prognostic indicator of extrahepatic bile duct cancer.
Breast Neoplasms
Activated matriptase as a target to treat breast cancer with a drug conjugate.
Breast Neoplasms
An investigation of the relationship between TMPRSS6 gene expression, genetic variants and clinical findings in breast cancer.
Breast Neoplasms
Coexpression of beta1,6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome.
Breast Neoplasms
Critical Adjuvant Influences on Preventive Anti-Metastasis Vaccine Using a Structural Epitope Derived from Membrane Type Protease PRSS14.
Breast Neoplasms
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Breast Neoplasms
Differential subcellular localization renders HAI-2 a matriptase inhibitor in breast cancer cells but not in mammary epithelial cells.
Breast Neoplasms
Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration.
Breast Neoplasms
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
Breast Neoplasms
HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease.
Breast Neoplasms
Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer.
Breast Neoplasms
Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer.
Breast Neoplasms
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Breast Neoplasms
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Breast Neoplasms
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Breast Neoplasms
Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.
Breast Neoplasms
Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.
Breast Neoplasms
Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.
Breast Neoplasms
N-Glycan Branching Affects the Subcellular Distribution of and Inhibition of Matriptase by HAI-2/Placental Bikunin.
Breast Neoplasms
N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease.
Breast Neoplasms
Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin.
Breast Neoplasms
Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases.
Breast Neoplasms
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk.
Breast Neoplasms
Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells.
Breast Neoplasms
Refinement of the 22q12-q13 Breast Cancer-Associated Region: Evidence of TMPRSS6 as a Candidate Gene in an Eastern Finnish Population.
Breast Neoplasms
ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.
Breast Neoplasms
Strong expression association between matriptase and its substrate prostasin in breast cancer.
Breast Neoplasms
Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.
Breast Neoplasms
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Breast Neoplasms
The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.
Breast Neoplasms
Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Breast Neoplasms
Type II transmembrane serine protease gene variants associate with breast cancer.
Burkitt Lymphoma
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Carcinogenesis
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
Carcinogenesis
Cell Surface Human Airway Trypsin-Like Protease Is Lost During Squamous Cell Carcinogenesis.
Carcinogenesis
Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase.
Carcinogenesis
Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis.
Carcinogenesis
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.
Carcinogenesis
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Carcinogenesis
Differential expression of genes encoding proteins of the HGF/MET system in insulinomas.
Carcinogenesis
Entosis and apical cell extrusion constitute a tumor-suppressive mechanism downstream of Matriptase.
Carcinogenesis
Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells.
Carcinogenesis
HAI-2 stabilizes, inhibits and regulates SEA-cleavage-dependent secretory transport of matriptase.
Carcinogenesis
Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth.
Carcinogenesis
Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itinerary.
Carcinogenesis
Insights into the regulation of the matriptase-prostasin proteolytic system.
Carcinogenesis
Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
Carcinogenesis
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Carcinogenesis
Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors.
Carcinogenesis
Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.
Carcinogenesis
Protease-activated receptor-2 accelerates intestinal tumor formation through activation of nuclear factor-?B signaling and tumor angiogenesis in ApcMin/+ mice.
Carcinogenesis
ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.
Carcinogenesis
Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis.
Carcinogenesis
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Carcinogenesis
The level of claudin-7 is reduced as an early event in colorectal carcinogenesis.
Carcinogenesis
The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals.
Carcinogenesis
Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
Carcinogenesis
TMPRSS13 promotes cell survival, invasion, and resistance to drug-induced apoptosis in colorectal cancer.
Carcinoma
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Carcinoma
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover.
Carcinoma
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.
Carcinoma
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
Carcinoma
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Carcinoma
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
Carcinoma
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Carcinoma
Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis.
Carcinoma
Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2.
Carcinoma
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.
Carcinoma
DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by down-regulating the EGFR/AKT pathway in esophageal squamous cell carcinoma.
Carcinoma
Differential subcellular localization renders HAI-2 a matriptase inhibitor in breast cancer cells but not in mammary epithelial cells.
Carcinoma
Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.
Carcinoma
Downexpression of Matriptase-2 Correlates With Tumor Progression and Clinical Prognosis in Oral Squamous-Cell Carcinoma.
Carcinoma
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Carcinoma
Entosis and apical cell extrusion constitute a tumor-suppressive mechanism downstream of Matriptase.
Carcinoma
Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
Carcinoma
Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.
Carcinoma
Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma.
Carcinoma
Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.
Carcinoma
Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells.
Carcinoma
Human Cancer Cells Retain Modest Levels of Enzymatically Active Matriptase Only in Extracellular Milieu following Induction of Zymogen Activation.
Carcinoma
In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Carcinoma
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Carcinoma
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Carcinoma
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Carcinoma
Matriptase activation of Gq drives epithelial disruption and inflammation via RSK and DUOX.
Carcinoma
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Carcinoma
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
Carcinoma
Matriptase is inhibited by extravascular antithrombin in epithelial cells but not in most carcinoma cells.
Carcinoma
Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1.
Carcinoma
Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes.
Carcinoma
Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis.
Carcinoma
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
Carcinoma
Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.
Carcinoma
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Carcinoma
Probing the interaction mechanism of small molecule inhibitors with matriptase based on molecular dynamics simulation and free energy calculations.
Carcinoma
Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin.
Carcinoma
Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors.
Carcinoma
Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1.
Carcinoma
Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue.
Carcinoma
Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer.
Carcinoma
Semiautomatic landmark-based two-dimensional-three-dimensional image fusion in living mice: correlation of near-infrared fluorescence imaging of Cy5.5-labeled antibodies with flat-panel volume computed tomography.
Carcinoma
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Carcinoma
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma.
Carcinoma
The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals.
Carcinoma
Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.
Carcinoma
Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.
Carcinoma, Basal Cell
Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer.
Carcinoma, Ductal
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
Carcinoma, Ductal
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Carcinoma, Endometrioid
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Carcinoma, Hepatocellular
Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.
Carcinoma, Hepatocellular
Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters.
Carcinoma, Intraductal, Noninfiltrating
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
Carcinoma, Intraductal, Noninfiltrating
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Carcinoma, Ovarian Epithelial
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Carcinoma, Papillary
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
Carcinoma, Renal Cell
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Carcinoma, Renal Cell
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Carcinoma, Renal Cell
Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.
Carcinoma, Renal Cell
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
Carcinoma, Squamous Cell
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
Carcinoma, Squamous Cell
Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis.
Carcinoma, Squamous Cell
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.
Carcinoma, Squamous Cell
DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by down-regulating the EGFR/AKT pathway in esophageal squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.
Carcinoma, Squamous Cell
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Carcinoma, Squamous Cell
Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes.
Carcinoma, Squamous Cell
Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer.
Carcinoma, Squamous Cell
Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.
Carcinoma, Transitional Cell
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Celiac Disease
The role of TMPRSS6 and HFE variants in iron deficiency anemia in celiac disease.
Celiac Disease
TMPRSS6 rs855791 Polymorphism Status in Children with Celiac Disease and Anemia.
Colitis
Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.
Colitis
Matriptase protects against experimental colitis and promotes intestinal barrier recovery.
Colitis
Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis.
Colitis, Ulcerative
Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.
Colitis, Ulcerative
Matriptase protects against experimental colitis and promotes intestinal barrier recovery.
Colonic Neoplasms
Discovery of novel 2-hydroxydiarylamide derivatives as TMPRSS4 inhibitors.
Colonic Neoplasms
Imaging a functional tumorigenic biomarker in the transformed epithelium.
Colonic Neoplasms
Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells.
Colorectal Neoplasms
A novel serine protease SNC19 associated with human colorectal cancer.
Colorectal Neoplasms
The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals.
Colorectal Neoplasms
Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.
Common Cold
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Coronavirus Infections
Biochemical Characterization of Middle East Respiratory Syndrome Coronavirus Spike Protein Proteolytic Processing.
Coronavirus Infections
TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection.
COVID-19
Characteristics of Angiotensin I-converting enzyme 2, type II transmembrane serine protease 2 and 4 in tree shrew indicate it as a potential animal model for SARS-CoV-2 infection.
COVID-19
Sex, Hormones, Immune Functions, and Susceptibility to Coronavirus Disease 2019 (COVID-19)-Related Morbidity.
COVID-19
TMPRSS2 Correlated With Immune Infiltration Serves as a Prognostic Biomarker in Prostatic Adenocarcinoma: Implication for the COVID-2019.
Crohn Disease
Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.
Crohn Disease
Matriptase protects against experimental colitis and promotes intestinal barrier recovery.
Cystic Fibrosis
Activity and inhibition of prostasin and matriptase on apical and basolateral surfaces of human airway epithelial cells.
Deafness
Mice deficient for the type II transmembrane serine protease, TMPRSS1/hepsin, exhibit profound hearing loss.
Deafness
Tmprss3, a transmembrane serine protease deficient in human DFNB8/10 deafness, is critical for cochlear hair cell survival at the onset of hearing.
Deafness
TMPRSS3, a type II transmembrane serine protease mutated in non-syndromic autosomal recessive deafness.
Dehydration
Activity and inhibition of prostasin and matriptase on apical and basolateral surfaces of human airway epithelial cells.
Diabetes Mellitus, Type 2
A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants.
Diabetes Mellitus, Type 2
Association of TMPRSS6 polymorphisms with ferritin, hemoglobin, and type 2 diabetes risk in a Chinese Han population.
Diabetes, Gestational
Associations of TMPRSS6 Polymorphisms with Gestational Diabetes Mellitus in Chinese Han Pregnant Women: a Preliminary Cohort Study.
Dysgerminoma
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Endodermal Sinus Tumor
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Endometrial Hyperplasia
Expression of matriptase and clinical outcome of human endometrial cancer.
Endometrial Neoplasms
Expression of matriptase and clinical outcome of human endometrial cancer.
Endometrial Neoplasms
Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells.
Esophageal Squamous Cell Carcinoma
Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.
Esophageal Squamous Cell Carcinoma
Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.
Fibroadenoma
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
Fibroadenoma
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Fibroma
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Fibrosarcoma
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk.
Genetic Diseases, Inborn
Matriptase Expression and Zymogen Activation in Human Pilosebaceous Unit.
Genetic Diseases, Inborn
Mutation G827R in Matriptase Causing Autosomal Recessive Ichthyosis with Hypotrichosis Yields an Inactive Protease.
Genetic Diseases, Inborn
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment.
Genetic Diseases, Inborn
The spatiotemporal control of human matriptase action on its physiological substrates: a case against a direct role for matriptase proteolytic activity in profilaggrin processing and desquamation.
Glioma
Aberrations in the Iron Regulatory Gene Signature Are Associated with Decreased Survival in Diffuse Infiltrating Gliomas.
Glioma
Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.
Glioma
Proteolytic cleavage of human acid-sensing ion channel 1 by the serine protease matriptase.
Granulosa Cell Tumor
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Hearing Loss
Mice deficient for the type II transmembrane serine protease, TMPRSS1/hepsin, exhibit profound hearing loss.
Hearing Loss
Tmprss3, a transmembrane serine protease deficient in human DFNB8/10 deafness, is critical for cochlear hair cell survival at the onset of hearing.
Hemochromatosis
Design and chemical syntheses of potent matriptase-2 inhibitors based on trypsin inhibitor SFTI-1 isolated from sunflower seeds.
Hemochromatosis
Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis.
Hemochromatosis
Genetic factors influencing hemoglobin levels in 15,567 blood donors: results from the Danish Blood Donor Study.
Hemochromatosis
Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
Hemochromatosis
Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
Hemochromatosis
Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activity-Based Probes of Matriptase-2.
Hemochromatosis
SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1.
Hemochromatosis
Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
Hemophilia A
[Detection of the heterozygote carrier state and prenatal diagnosis of hemophilia A using DNA probes]
Hepatitis C, Chronic
Hepcidin in Iron Homeostasis: Diagnostic and Therapeutic Implications in Type 2 Diabetes Mellitus Patients.
Hyperferritinemia
Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy.
Hypersensitivity
[Association of FokI rs2228570 and TMPRSS6 rs855791 polymorphisms with cow's milk protein allergy in children].
Hypohidrosis
A novel mutation in ST14 at a functionally significant amino acid residue expands the spectrum of ichthyosis-hypotrichosis syndrome.
Hypohidrosis
Matriptase Regulates Proliferation and Early, but Not Terminal, Differentiation of Human Keratinocytes.
Hypotrichosis
A novel mutation in ST14 at a functionally significant amino acid residue expands the spectrum of ichthyosis-hypotrichosis syndrome.
Hypotrichosis
Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice.
Hypotrichosis
Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase.
Hypotrichosis
Autosomal recessive ichthyosis with hypotrichosis syndrome: further delineation of the phenotype.
Hypotrichosis
Ichthyosis, Follicular Atrophoderma, and Hypotrichosis Caused by Mutations in ST14 Is Associated with Impaired Profilaggrin Processing.
Hypotrichosis
Matriptase Regulates Proliferation and Early, but Not Terminal, Differentiation of Human Keratinocytes.
Hypotrichosis
Mutation G827R in Matriptase Causing Autosomal Recessive Ichthyosis with Hypotrichosis Yields an Inactive Protease.
Hypotrichosis
The matriptase-prostasin proteolytic cascade in epithelial development and pathology.
Ichthyosis
A novel mutation in ST14 at a functionally significant amino acid residue expands the spectrum of ichthyosis-hypotrichosis syndrome.
Ichthyosis
Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice.
Ichthyosis
Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase.
Ichthyosis
Autosomal recessive ichthyosis with hypotrichosis syndrome: further delineation of the phenotype.
Ichthyosis
Ichthyosis, Follicular Atrophoderma, and Hypotrichosis Caused by Mutations in ST14 Is Associated with Impaired Profilaggrin Processing.
Ichthyosis
Loss of Matriptase Suppression Underlies Spint1 Mutation-Associated Ichthyosis and Postnatal Lethality.
Ichthyosis
Matriptase Cleaves EpCAM and TROP2 in Keratinocytes, Destabilizing Both Proteins and Associated Claudins.
Ichthyosis
Matriptase Regulates Proliferation and Early, but Not Terminal, Differentiation of Human Keratinocytes.
Ichthyosis
Mutation G827R in Matriptase Causing Autosomal Recessive Ichthyosis with Hypotrichosis Yields an Inactive Protease.
Idiopathic Pulmonary Fibrosis
Matriptase, Protease-activated Receptor 2, and Idiopathic Pulmonary Fibrosis. Further Evidence for Signaling Pathway Redundancy in this Difficult-to-Treat Disease?
Infections
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
Infections
Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression.
Infections
Hepcidin in Iron Homeostasis: Diagnostic and Therapeutic Implications in Type 2 Diabetes Mellitus Patients.
Infections
Matriptase activation connects tissue factor-dependent coagulation initiation to epithelial proteolysis and signaling.
Infections
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection Mediated by the Transmembrane Serine Protease TMPRSS2.
Infections
The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2.
Inflammatory Breast Neoplasms
Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.
Influenza, Human
Cleavage Activation of the Human-Adapted Influenza Virus Subtypes by Matriptase Reveals both Subtype and Strain Specificities.
Influenza, Human
DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry.
Influenza, Human
Evidence that TMPRSS2 activates the SARS-coronavirus spike-protein for membrane fusion and reduces viral control by the humoral immune response.
Influenza, Human
Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation.
Influenza, Human
Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium.
Influenza, Human
Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses.
Influenza, Human
Non-human primate orthologues of TMPRSS2 cleave and activate the influenza virus hemagglutinin.
Influenza, Human
SPINT2 inhibits proteases involved in activation of both influenza viruses and metapneumoviruses.
Insulin Resistance
Matriptase-2 deficiency protects from obesity by modulating iron homeostasis.
Insulinoma
Differential expression of genes encoding proteins of the HGF/MET system in insulinomas.
Intestinal Failure
Matriptase drives early-onset intestinal failure in a mouse model of congenital tufting enteropathy.
Iron Deficiencies
Anaemia, iron deficiency and a common polymorphism of iron-regulation, TMPRSS6 rs855791, in Rwandan children.
Iron Deficiencies
Common TMPRSS6 mutations and iron, erythrocyte, and pica phenotypes in 48 women with iron deficiency or depletion.
Iron Deficiencies
Does TMPRSS6 RS855791 polymorphism contribute to iron deficiency in treated celiac disease?
Iron Deficiencies
Effect of Erythropoietin, Iron Deficiency and Iron Overload on Liver Matriptase-2 (TMPRSS6) Protein Content in Mice and Rats.
Iron Deficiencies
Heeney MM, Guo D, De Falco L, et al. Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood. 2018;132(4):448-452.
Iron Deficiencies
Iron deficiency anemia due to matriptase-2 inactivation is dependent upon the presence of functional Bmp6.
Iron Deficiencies
Iron Refractory Iron Deficiency Anaemia: A Rare Cause of Iron Deficiency Anaemia.
Iron Deficiencies
Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis.
Iron Deficiencies
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
Iron Deficiencies
Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model.
Iron Deficiencies
Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency.
Iron Deficiencies
Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6.
Iron Deficiencies
Study the association of transmembrane serine protease 6 gene polymorphisms with iron deficiency status in Saudi Arabia.
Iron Deficiencies
Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/TMPRSS6.
Iron Deficiencies
The erythroid function of Transferrin Receptor 2 revealed by Tmprss6inactivation in different models of Transferrin Receptor 2 knock out mice.
Iron Deficiencies
The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin.
Iron Deficiencies
Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
Iron Deficiencies
TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia.
Iron Deficiencies
Transferrin Receptor 1 Regulates Thermogenic Capacity and Cell Fate in Brown/Beige Adipocytes.
Iron Deficiencies
Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency.
Iron Metabolism Disorders
A child with severe iron-deficiency anemia and a complex TMPRSS6 genotype.
Iron Metabolism Disorders
A novel homozygous nonsense mutation (p.Y78*) in TMPRSS6 gene causing iron-refractory iron deficiency anemia (IRIDA) in two siblings.
Iron Metabolism Disorders
Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.
Iron Overload
3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach.
Iron Overload
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.
Iron Overload
A strong anti-inflammatory signature revealed by liver transcription profiling of Tmprss6-/- mice.
Iron Overload
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine ?-thalassemia intermedia.
Iron Overload
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of ?-thalassemia intermedia.
Iron Overload
Deletion of TMPRSS6 attenuates the phenotype in a mouse model of ?-thalassemia.
Iron Overload
Design and chemical syntheses of potent matriptase-2 inhibitors based on trypsin inhibitor SFTI-1 isolated from sunflower seeds.
Iron Overload
Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis.
Iron Overload
Effect of Erythropoietin, Iron Deficiency and Iron Overload on Liver Matriptase-2 (TMPRSS6) Protein Content in Mice and Rats.
Iron Overload
En Route to New Therapeutic Options for Iron Overload Diseases: Matriptase-2 as a Target for Kunitz-Type Inhibitors.
Iron Overload
Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
Iron Overload
Hepatocyte growth factor activator inhibitor type 2 (HAI-2) modulates hepcidin expression by inhibiting the cell surface protease matriptase-2.
Iron Overload
Iron deficiency anemia due to matriptase-2 inactivation is dependent upon the presence of functional Bmp6.
Iron Overload
Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
Iron Overload
Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
Iron Overload
RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of ?-thalassemia intermedia.
Iron Overload
SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1.
Iron Overload
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of ?-thalassaemia.
Iron Overload
The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.
Iron Overload
[Iron deficiency and overload. Implications in oxidative stress and cardiovascular health]
Kidney Failure, Chronic
Associations of Common Variants in HFE and TMPRSS6 Genes with Hepcidin-25 and Iron Status Parameters in Patients with End-Stage Renal Disease.
Leukemia
Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains.
Leukemia, Lymphocytic, Chronic, B-Cell
Matriptase is highly upregulated in chronic lymphocytic leukemia and promotes cancer cell invasion.
Leukemia, Myeloid, Acute
[Expression and Clinical Significances of HGFA, Matriptase, HAI-1 and HAI-2 in Acute Myeloid Leukemia].
Leukemia, Myeloid, Acute
[Expression level and Clinical Significance of Serum SE-CAD and Matriptase in Patients with Acute Myeloid Leukemia].
Liver Cirrhosis
Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis.
Liver Diseases
The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.
Lung Injury
Membrane-anchored Serine Protease Matriptase is a Trigger of Pulmonary Fibrogenesis.
Lung Neoplasms
Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin.
Lymphatic Metastasis
Expression and prognostic value of matriptase in ovarian serous adenocarcinoma.
Lymphatic Metastasis
Expression of matriptase and clinical outcome of human endometrial cancer.
Lymphatic Metastasis
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Lymphoma
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Lymphoma, B-Cell
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Lymphoma, Follicular
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
matriptase deficiency
Decreased hemojuvelin protein levels in mask mice lacking matriptase-2-dependent proteolytic activity.
matriptase deficiency
EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency.
matriptase deficiency
Matriptase Regulates Proliferation and Early, but Not Terminal, Differentiation of Human Keratinocytes.
matriptase deficiency
Matriptase-2 deficiency protects from obesity by modulating iron homeostasis.
matriptase deficiency
The spatiotemporal control of human matriptase action on its physiological substrates: a case against a direct role for matriptase proteolytic activity in profilaggrin processing and desquamation.
Melanoma
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Mesothelioma, Malignant
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.
Milk Hypersensitivity
[Association of FokI rs2228570 and TMPRSS6 rs855791 polymorphisms with cow's milk protein allergy in children].
Neoplasm Metastasis
?-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Neoplasm Metastasis
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.
Neoplasm Metastasis
Addition of beta1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin.
Neoplasm Metastasis
Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.
Neoplasm Metastasis
Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway.
Neoplasm Metastasis
Curcumin-targeting Pericellular Serine Protease Matriptase Role in Suppression of Prostate Cancer Cell Invasion, Tumor Growth and Metastasis.
Neoplasm Metastasis
Decreasing the ratio of matriptase/HAI?1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer.
Neoplasm Metastasis
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Neoplasm Metastasis
Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein.
Neoplasm Metastasis
Differential expression of genes encoding proteins of the HGF/MET system in insulinomas.
Neoplasm Metastasis
Discovery of novel 2-hydroxydiarylamide derivatives as TMPRSS4 inhibitors.
Neoplasm Metastasis
Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.
Neoplasm Metastasis
Downexpression of Matriptase-2 Correlates With Tumor Progression and Clinical Prognosis in Oral Squamous-Cell Carcinoma.
Neoplasm Metastasis
Dysregulated HAI-2 Plays an Important Role in Renal Cell Carcinoma Bone Metastasis through Ligand-Dependent MET Phosphorylation.
Neoplasm Metastasis
Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
Neoplasm Metastasis
Expression and prognostic value of matriptase in ovarian serous adenocarcinoma.
Neoplasm Metastasis
Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: Clinical and biological significance.
Neoplasm Metastasis
Expression of matriptase and clinical outcome of human endometrial cancer.
Neoplasm Metastasis
Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
Neoplasm Metastasis
HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase.
Neoplasm Metastasis
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Neoplasm Metastasis
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Neoplasm Metastasis
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Neoplasm Metastasis
Intramembrane proteolysis of an extracellular serine protease, epithin/PRSS14, enables its intracellular nuclear function.
Neoplasm Metastasis
Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer.
Neoplasm Metastasis
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
Neoplasm Metastasis
Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.
Neoplasm Metastasis
Shedding of epithin/PRSS14 is induced by TGF-? and mediated by tumor necrosis factor-? converting enzyme.
Neoplasm Metastasis
Soluble epithin/PRSS14 secreted from cancer cells contains active angiogenic potential.
Neoplasm Metastasis
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
Neoplasm Metastasis
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Neoplasm Metastasis
Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Neoplasm Metastasis
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Neoplasm Metastasis
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Neoplasm Metastasis
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Neoplasm Metastasis
The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.
Neoplasm Metastasis
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma.
Neoplasm Metastasis
TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients.
Neoplasm Metastasis
[Study on post-translational processing and active forms of the novel metastasis-associated protein SNC19]
Neoplasms
3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation.
Neoplasms
?-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Neoplasms
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Neoplasms
A pan-cancer analysis of alternative splicing events reveals novel tumor-associated splice variants of matriptase.
Neoplasms
A supramolecular nanocarrier for efficient cancer imaging and therapy by targeting at matriptase.
Neoplasms
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.
Neoplasms
Addition of beta1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin.
Neoplasms
An investigation of the relationship between TMPRSS6 gene expression, genetic variants and clinical findings in breast cancer.
Neoplasms
Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.
Neoplasms
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
Neoplasms
Cell Surface Human Airway Trypsin-Like Protease Is Lost During Squamous Cell Carcinogenesis.
Neoplasms
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Neoplasms
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
Neoplasms
Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase.
Neoplasms
Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1.
Neoplasms
Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway.
Neoplasms
Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1.
Neoplasms
Curcumin-targeting Pericellular Serine Protease Matriptase Role in Suppression of Prostate Cancer Cell Invasion, Tumor Growth and Metastasis.
Neoplasms
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Neoplasms
Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients.
Neoplasms
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.
Neoplasms
Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein.
Neoplasms
Differential Tumorigenic Potential and Matriptase Activation between PDGF B versus PDGF D in Prostate Cancer.
Neoplasms
Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.
Neoplasms
Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Neoplasms
Downexpression of Matriptase-2 Correlates With Tumor Progression and Clinical Prognosis in Oral Squamous-Cell Carcinoma.
Neoplasms
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Neoplasms
Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.
Neoplasms
Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition.
Neoplasms
Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration.
Neoplasms
Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
Neoplasms
Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.
Neoplasms
Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: Clinical and biological significance.
Neoplasms
Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma.
Neoplasms
Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.
Neoplasms
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Neoplasms
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
Neoplasms
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
Neoplasms
Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.
Neoplasms
Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
Neoplasms
Gold nanoparticles based molecular beacons for in vitro and in vivo detection of the matriptase expression on tumor.
Neoplasms
HAI-2 stabilizes, inhibits and regulates SEA-cleavage-dependent secretory transport of matriptase.
Neoplasms
HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase.
Neoplasms
HATL5: A Cell Surface Serine Protease Differentially Expressed in Epithelial Cancers.
Neoplasms
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Neoplasms
High expression level of TMPRSS4 predicts adverse outcomes of colorectal cancer patients.
Neoplasms
Human Cancer Cells Retain Modest Levels of Enzymatically Active Matriptase Only in Extracellular Milieu following Induction of Zymogen Activation.
Neoplasms
Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.
Neoplasms
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Neoplasms
Improving the species cross-reactivity of an antibody using computational design.
Neoplasms
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Neoplasms
Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters.
Neoplasms
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Neoplasms
Inhibition of an active zymogen protease: the zymogen form of matriptase is regulated by HAI-1 and HAI-2.
Neoplasms
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Neoplasms
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Neoplasms
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
Neoplasms
Intramembrane proteolysis of an extracellular serine protease, epithin/PRSS14, enables its intracellular nuclear function.
Neoplasms
Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis.
Neoplasms
Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer.
Neoplasms
Knockdown of TMPRSS3, a Transmembrane Serine Protease, Inhibits the Proliferation, Migration, and Invasion in Human Nasopharyngeal Carcinoma Cells.
Neoplasms
Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis.
Neoplasms
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Neoplasms
Matriptase activation connects tissue factor-dependent coagulation initiation to epithelial proteolysis and signaling.
Neoplasms
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Neoplasms
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Neoplasms
Matriptase is highly upregulated in chronic lymphocytic leukemia and promotes cancer cell invasion.
Neoplasms
Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors.
Neoplasms
Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.
Neoplasms
Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.
Neoplasms
Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.
Neoplasms
Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.
Neoplasms
Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis.
Neoplasms
Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1.
Neoplasms
Metabolism and distribution of two highly potent and selective peptidomimetic inhibitors of matriptase.
Neoplasms
Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention.
Neoplasms
Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.
Neoplasms
Overexpression of matriptase in tumor stroma is a poor prognostic indicator of extrahepatic bile duct cancer.
Neoplasms
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Neoplasms
Polyserase-1/TMPRSS9 induces pro-tumor effects in pancreatic cancer cells by activation of pro-uPA.
Neoplasms
Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.
Neoplasms
Probing the interaction mechanism of small molecule inhibitors with matriptase based on molecular dynamics simulation and free energy calculations.
Neoplasms
Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin.
Neoplasms
Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
Neoplasms
Protease-activated receptor-2 accelerates intestinal tumor formation through activation of nuclear factor-?B signaling and tumor angiogenesis in ApcMin/+ mice.
Neoplasms
Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis.
Neoplasms
PRSS14/Epithin is induced in macrophages by the IFN-?/JAK/STAT pathway and mediates transendothelial migration.
Neoplasms
Rapid Assessment of Surface Markers on Cancer Cells Using Immuno-Magnetic Separation and Multi-frequency Impedance Cytometry for Targeted Therapy.
Neoplasms
Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.
Neoplasms
Shedding of epithin/PRSS14 is induced by TGF-? and mediated by tumor necrosis factor-? converting enzyme.
Neoplasms
Soluble epithin/PRSS14 secreted from cancer cells contains active angiogenic potential.
Neoplasms
Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities.
Neoplasms
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
Neoplasms
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Neoplasms
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Neoplasms
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Neoplasms
Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.
Neoplasms
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Neoplasms
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Neoplasms
The influence of matriptase-2 on prostate cancer in vitro: A possible role for ?-catenin.
Neoplasms
The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
Neoplasms
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma.
Neoplasms
The type II transmembrane serine protease matriptase-2--identification, structural features, enzymology, expression pattern and potential roles.
Neoplasms
The type II transmembrane serine protease, matriptase-2: Possible links to cancer?
Neoplasms
Time-domain in vivo near infrared fluorescence imaging for evaluation of matriptase as a potential target for the development of novel, inhibitor-based tumor therapies.
Neoplasms
TMPRSS13 promotes cell survival, invasion, and resistance to drug-induced apoptosis in colorectal cancer.
Neoplasms
TMPRSS2 Correlated With Immune Infiltration Serves as a Prognostic Biomarker in Prostatic Adenocarcinoma: Implication for the COVID-2019.
Neoplasms
TMPRSS4 correlates with colorectal cancer pathological stage and regulates cell proliferation and self-renewal ability.
Neoplasms
TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients.
Neoplasms
TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways.
Neoplasms
TMPRSS4 induces invasion and proliferation of prostate cancer cells through induction of Slug and cyclin D1.
Neoplasms
TMPRSS4 is a type II transmembrane serine protease involved in cancer and viral infections.
Neoplasms
TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion.
Neoplasms
Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.
Neoplasms
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Neoplasms
Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.
Neoplasms
[Study on post-translational processing and active forms of the novel metastasis-associated protein SNC19]
Netherton Syndrome
Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.
Netherton Syndrome
Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Neural Tube Defects
Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice.
Neuroblastoma
Matriptase cleaves the amyloid-beta peptide 1-42 at Arg-5, Lys-16, and Lys-28.
Non-alcoholic Fatty Liver Disease
The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.
Osteoarthritis
Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors.
Osteoarthritis
Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein.
Osteoarthritis
Matriptase Induction of Metalloproteinase-Dependent Aggrecanolysis In Vitro and In Vivo: Promotion of Osteoarthritic Cartilage Damage by Multiple Mechanisms.
Osteoarthritis
Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis.
Osteoarthritis
Protease activated receptor 2 and matriptase expression in the joints of cats with and without osteoarthritis.
Ovarian Neoplasms
Decreasing the ratio of matriptase/HAI?1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer.
Ovarian Neoplasms
Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
Ovarian Neoplasms
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Ovarian Neoplasms
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Ovarian Neoplasms
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Ovarian Neoplasms
Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.
Ovarian Neoplasms
[Expression and significance of matriptase in ovarian cancer cells with diverse metastatic potential].
Pancreatic Neoplasms
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Examination of HFE associations with childhood leukemia risk and extension to other iron regulatory genes.
Prostatic Hyperplasia
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Prostatic Intraepithelial Neoplasia
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Prostatic Neoplasms
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Prostatic Neoplasms
Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.
Prostatic Neoplasms
Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.
Prostatic Neoplasms
Author Correction: The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
Prostatic Neoplasms
Curcumin-targeting Pericellular Serine Protease Matriptase Role in Suppression of Prostate Cancer Cell Invasion, Tumor Growth and Metastasis.
Prostatic Neoplasms
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Prostatic Neoplasms
Development of an Activatable Fluorescent Probe for Prostate Cancer Imaging.
Prostatic Neoplasms
Differential Tumorigenic Potential and Matriptase Activation between PDGF B versus PDGF D in Prostate Cancer.
Prostatic Neoplasms
Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.
Prostatic Neoplasms
Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.
Prostatic Neoplasms
Dynamic regulation of platelet-derived growth factor D (PDGF-D) activity and extracellular spatial distribution by matriptase-mediated proteolysis.
Prostatic Neoplasms
Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
Prostatic Neoplasms
From in-silico to Experimental Validation: Tailoring Peptide Substrates for a Serine Protease.
Prostatic Neoplasms
Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.
Prostatic Neoplasms
Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
Prostatic Neoplasms
HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase.
Prostatic Neoplasms
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Prostatic Neoplasms
Hepsin inhibits CDK11p58 IRES activity by suppressing unr expression and eIF-2? phosphorylation in prostate cancer.
Prostatic Neoplasms
HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes from Human Hepsin as Novel Targets for Prostate Cancer Immunotherapy.
Prostatic Neoplasms
Identification and characterization of small-molecule inhibitors of hepsin.
Prostatic Neoplasms
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Prostatic Neoplasms
Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
Prostatic Neoplasms
Loss of the matriptase inhibitor HAI-2 during prostate cancer progression.
Prostatic Neoplasms
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Prostatic Neoplasms
Matriptase Is Involved in ErbB-2-Induced Prostate Cancer Cell Invasion.
Prostatic Neoplasms
Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis.
Prostatic Neoplasms
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Prostatic Neoplasms
Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Prostatic Neoplasms
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Prostatic Neoplasms
The influence of matriptase-2 on prostate cancer in vitro: A possible role for ?-catenin.
Prostatic Neoplasms
The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
Prostatic Neoplasms
TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.
Pulmonary Fibrosis
Membrane-anchored Serine Protease Matriptase is a Trigger of Pulmonary Fibrogenesis.
Renal Insufficiency, Chronic
TMPRSS6 rs855791 polymorphism and susceptibility to iron deficiency anaemia in non-dialysis chronic kidney disease patients in South Africa.
Restless Legs Syndrome
Genetic factors influencing hemoglobin levels in 15,567 blood donors: results from the Danish Blood Donor Study.
Sarcoma
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Severe Acute Respiratory Syndrome
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
Severe Acute Respiratory Syndrome
Sex, Hormones, Immune Functions, and Susceptibility to Coronavirus Disease 2019 (COVID-19)-Related Morbidity.
Severe Acute Respiratory Syndrome
Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.
Skin Diseases
Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Skin Neoplasms
Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer.
Squamous Cell Carcinoma of Head and Neck
Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2.
Squamous Cell Carcinoma of Head and Neck
Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma.
Stomach Neoplasms
Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis.
Stomach Neoplasms
Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching.
Stomach Neoplasms
TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition.
Thalassemia
Design and chemical syntheses of potent matriptase-2 inhibitors based on trypsin inhibitor SFTI-1 isolated from sunflower seeds.
Thalassemia
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment.
Thalassemia
The V736A TMPRSS6 polymorphism influences liver iron concentration in nontransfusion-dependent thalassemias.
Thrombocytosis
Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Humans and Mice.
Thromboembolism
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Thymoma
Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration.
Thymoma
Soluble epithin/PRSS14 secreted from cancer cells contains active angiogenic potential.
Thyroid Neoplasms
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
Triple Negative Breast Neoplasms
Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.
Urinary Bladder Neoplasms
Expression of protease activating receptor-2 (PAR-2) is positively correlated with the recurrence of non-muscle invasive bladder cancer: an immunohistochemical analysis.
Urinary Bladder Neoplasms
Ibuprofen regulates the expression and function of membrane-associated serine proteases prostasin and matriptase.
Urinary Bladder Neoplasms
Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis.
Urologic Neoplasms
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Uterine Cervical Neoplasms
A novel serine protease SNC19 associated with human colorectal cancer.
Virus Diseases
TMPRSS4 is a type II transmembrane serine protease involved in cancer and viral infections.
html completed